vaccinia

Envelopped viruses (HBV, HCV, HIV, Vaccinia),

Envelopped Viren (HBV, HCV, HIV, Vaccinia),

Envelopped viruses (Bird flu, HBV, HCV, HIV, Vaccinia),

Envelopped Viren (Vogelgrippe, HBV, HCV, HIV, Vaccinia)

(incl. HBV, HCV, HIV, Vaccinia, BVDV)

(inkl. HBV, HCV, HIV, Vaccinia, BVDV)

(incl. HBV, HCV, HIV, vaccinia virus, BVDV)

(inkl. HBV, HCV, HIV, Vaccinia Virus BVDV)

To show that there are no cross reactions between the wildtype strain and the 3B3 mouse monoclonal antibody as well as between the primary and secondary antibodies an additional staining of the wildtype is performed where the anti vaccinia antibody in the antibody working solution 1 is replaced by PBS-Z.

Um zu zeigen, dass es keine Kreuzreaktionen zwischen dem Wildtyp-Stamm und dem monoklonalen Maus-Antikörper 3B3 sowie zwischen den primären und sekundären Antikörper eine zusätzliche Färbung des Wildtyp durchgeführt wird, wo das Anti Pocken-Antikörper der Antikörper Arbeitslösung 1 durch PBS ersetzt -Z.

OP preparation for the determination of-tumor cells (e.g. edge of removal, ensuring the extent of resection) Lymph nodes for the detection of metastases and tumor cells (“microenvolvement”) Lavage for the determination of disseminated tumor cells in the peritoneal cavity Tissue for the determination of disseminated tumor cells (immunohistochemistry) Differential diagnosis of carcinomas immunohistochemical determination of characteristic E-cadherin mutations for differential diagnostic evaluation of suspected tissue samples Screening of high-risk groups (“cancer families”) determination of E-cadherin mutations in blood cells (DNA) in vivo Prerequisite: humanization of the antibody for therapeutic use specific determination of tumor cells by immunoscintigraphy: pre-therapeutically for set up of operation plan/therapy plan for the control of the course of therapy or, respectively, for the verification of a successful therapy and for the control of the post-therapeutical course of the disease Therapy by mutation-specific E-cadherin antibodies: immunoradiotherapy coupling of a source of radiation to the mutation-specific antibody immunotoxin therapy coupling of a toxin (e.g. pseudomonas toxin) to the antibody Somatic gene therapy by mutation-specific E-cadherin antibodies: possible ways for a specific gene transfer: coupling to viral gene expression systems (e.g. adenovirus, or MVA, vaccinia-derived expression vectors); coupling to non-viral gene expression systems (e.g. T7 RNA polymerase+T7 DNA vector); Possible therapy approach using genetic engineering: incorporation of cofactors (e.g. B7) to label the tumor cells for the endogenous immune system; incorporation of alloantigens (foreign HLA antigens, “major antigens”) to activate the endogenous T cells and initiate an immune reaction against tumor cells having mutated E-cadherin “minor antigen”); killing of tumor cells by specific incorporation of factors inducing apoptosis (e.g. p53); conversion of the malignant phenotype by specific incorporation of wildtype oncogenes/suppressor genes (e.g. E-cadherin itself); activation of a protoxin to form a toxin by specific inclusion of an enzyme (e.g. cytosin deaminase, conversion of 5-fluoro cytosin into the toxic 5-fluoro uracil); Ribozymes e.g. site-specific destruction of the RNA coding for the multidrug-resistance transporter Further examples showing fields of use of the E-cadherin mutations bone marrow purching: specific determination of tumor cells in treated bone marrow in vitro and concurrent use of the antibody for specific elimination of tumor cells from the bone marrow (e.g. by a toxin bound to the antibody); immune therapy charging of dendritic cells with mutated E-cadherin peptide sequences (see Table 3) for antigen presentation (activation of T cell clones specifically directed against tumor cells).

Prospektive Untersuchung in vitro von Therapie mittels mutations-spezifischer E-Cadherin Antikörper: Somatische Gentherapie mittels mutations-spezifischer E-Cadherin Antikörper: Weitere Beispiele von Anwendungsbereichen der E-Cadherin Mutationen Beim intrazellulären Abbau von Proteinen entstehen Peptide mit unterschiedlicher Länge.

[0015] The invention furthermore relates to the use of descendants of the strains according is to the invention, which descendants are obtained by passaging or adaptation to suitable cell systems, for example human cells, such as WI-38, MRC-5, monkey cells e.g. Vero cells, bovine cells such as BK-K13A47/Reg or MDBK, and ovine cells, such as MDOK, for producing medicaments against viral infections and cancer in humans and animals, and also relates to the use of parts or fragments of the said strains, and their passaging and adaptation variants, where parts are to be understood as being genomic or subgenomic fragments which are expressed with the aid of suitable vectors, such as vaccinia viruses, in suitable systems, such as fibroblast cell cultures and fragments are to be understood as being the fractions, which are obtained by biochemical purification, such as chromatography, of the expressed or physically disrupted viral particles, for producing medicaments which are directed against viral infections and cancer in humans and animals, and also relates to the use of one of the strains of Parapoxvirus ovis, and of derivatives which are derived as described above, for producing medicaments and pharmaceutical preparations as immunotherapeutic agents or immunoprophylactic agents for autoimmune diseases and for acute and chronic viral infections of the respiratory tract and the internal organs, and also relates to the use of one of the strains, and of derived derivatives, for producing medicaments and pharmaceutical preparations for stress metaphylaxis and for preventing or averting infectious diseases following stress and also in connection with infection prophylaxis within the context of operations and dental interventions, and also relates to the use of one of the strains, and of derived derivatives, for producing medicaments and pharmaceutical preparations for use in infection metaphylaxis or the therapy of acute and chronic viral infections, for example of the respiratory tract, of papilloma virus infections, of infection with viruses of the herpes group, of HIV infection, or of viral infection of internal organs, such as infection with hepatitis viruses, and also use in connection with diseases such as multiple sclerosis, asthma, warts and other neoformations of the skin, and also relates to the use of one of the strains, and of derived derivatives, for producing medicaments and pharmaceutical preparations for use on wounds, for accelerating wound healing processes, and use for supporting the healing of wounds which only heal poorly or which do not heal at all and ulcer of the leg, and also relates to the use of one of the strains, and of derived derivatives, for producing medicaments and pharmaceutical preparations for use for diseases of the spectrum of allergic diseases, psoriasis, neurodermatitis and other autoimmune diseases, such as lupus erythematodes, and also for improving wellbeing, for example in elderly patients, and also relates to the use of one of the strains, and of derived derivatives, for producing medicaments and pharmaceutical preparations for use against inflammatory, degenerative and proliferative diseases of the internal organs, for example Crohn's diseases, of the skin, of the blood, of the central nervous system and its appended structures, and including the eye, including cancer, and also relates to the use of one of the strains, and of derived derivatives, in combination with other remedies for producing medicaments and pharmaceutical preparations for antiviral therapy or cancer therapy in humans and animals.

Weiterhin betrifft die Erfindung die Verwendung von durch Passagierung oder Adaptation an geeigneten Zellsystemen wie beispielsweise humanen Zellen wie WI-38, MRC-5, Affenzellen, z.B. Vero-Zellen, bovine Zellen wie z.B. BK-K13A47/Reg oder MDBK, und ovinen Zellen wie MDOK, erhaltenen Abkömmlingen des erfindungsgemäßen Stammes zur Herstellung von Arzneimitteln gegen virale Infektionen und Krebs bei Mensch und Tier zum Gegenstand hat, und weiter die Verwendung von Teilen oder Bruchstücken des genannten Stammes und seiner Passagierungs- und Adaptationsvarianten, wobei unter Teilen mittels geeigneter Vektoren wie Vacciniaviren in geeigneten Systemen wie Fibroblastenzellkulturen exprimierte genomische oder subgenomische Fragmente und unter Bruchstücken die durch biochemische Aufreinigung wie Chromatografie erhaltenen Fraktionen der exprimierten oder physikalisch aufgeschlossenen viralen Partikel zu verstehen sind, zur Herstellung von Arzneimitteln gegen virale Infektionen und Krebs bei Mensch und Tier zum Gegenstand hat, und weiter die Verwendung des Stammes von Parapoxvirus ovis und wie vorstehend beschrieben abgeleiteten Derivate zur Herstellung von Arzneimitteln und pharmazeutischen Zubereitungen als Immuntherapeutika oder Immunprophylaktika bei akuten und chronischen viralen Infektionen des Respirationstraktes und der inneren Organe, zum Gegenstand hat, und weiter die Verwendung des Stammes und abgeleiteten Derivate zur Herstellung von Arzneimitteln und pharmazeutischen Zubereitungen für die Stressmetaphylaxe und zur Verhinderung oder Vorbeugung von Infektionskrankheiten nach Stress sowie bei der Infektionsprophylaxe im Rahmen von Operationen und zahnärztlichen Eingriffen zum Gegenstand hat, und weiter die Verwendung des Stammes und abgeleiteten Derivate zur Herstellung von Arzneimitteln und pharmazeutischen Zubereitungen für die Verwendung bei der Infektionsmetaphylaxe oder Therapie akuter und chronischer viraler Infektionen beispielsweise des Respirationstraktes, der Papillomvirusinfektionen, der Infektion mit Viren der Herpesgruppe, der HIV-Infektion, der Virusinfektion innerer Organe wie beispielsweise der Infektion mit Hepatitisviren und weiter die Verwendung des Stammes und abgeleiteter Derivate zur Herstellung von Arzneimitteln und pharmazeutischen Zubereitungen für die Verwendung gegen Krebs zum Gegenstand hat, und weiter die Verwendung des Stammes und davon abgeleiteter Derivate in Kombination mit anderen Mitteln zur Herstellung von Arzneimitteln und pharmazeutischen Zubereitungen zur antiviralen- oder Krebstherapie bei Mensch und Tier zum Gegenstand hat.